
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare has demonstrated a stable gross margin of 20.0% for the most recent quarter, maintaining this figure from the previous quarter and surpassing estimated expectations. The announced acquisition by Aya Healthcare at $18.61 per share represents a substantial 67% premium to Cross Country's share price prior to the announcement, highlighting the perceived intrinsic value of the company. Additionally, the revised timeline for the transaction's closure to the second half of 2025 suggests strategic planning and confidence in Cross Country’s future financial performance.
Bears say
Cross Country Healthcare reported a significant decline in adjusted EBITDA, which fell 44% year-over-year to $8.6 million in Q1/25, despite exceeding estimates. The company's Q1/25 revenue of $293.4 million was not only below both internal and consensus estimates but also represented a substantial 23% year-over-year decrease, primarily attributed to ongoing weaker demand in the healthcare travel staffing sector. Additionally, following these disappointing results, the revenue estimate for 2025 was revised down to $1.166 billion, reflecting a 13.3% year-over-year decline from the previously anticipated figure.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares